AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration
Launch of Major Product Expected to Significantly Drive Performance Growth HONG KONG,March 12,2025-- AIM Vaccine Co.,Ltd. (06660.HK),a leading PRC vaccine company,published an announcement on March 12